anti-TIGIT antibody · antibody
tiragolumab
1 active trials across 2 of our biomarkers, targeting TIGIT. Not approved for any biomarker on marked.bio yet.
Also known as MTIG7192A, RG6058.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 1 | 1 | Phase 2 |
| MSI-H / dMMR | 0 | 2 | – |
Trials
1 of 3 trials shown
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
tiragolumabatezolizumabbevacizumab
Confirmed activating alteration in EGFR (cohort B only)
EGFR exon 19 deletion / L858RNon-squamous Non-small-cell Lung Cancer
-
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
…ancer, head and neck cancer and any other tumor type with known high TMB (≥ 13 mut/MB) or MSI-H
MSI-H / dMMRSolid Tumors
-
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
MSI-high solid tumors as defined by local testing for MSI/MMR will also be included.
MSI-H / dMMRNon-Small Cell Lung Cancer, Solid Tumor
No trials match these filters.